A Comparison of the Diagnostic Sensitivity of MRI, CBF-SPECT, FDG-PET and Cerebrospinal Fluid Biomarkers for Detecting Alzheimer's Disease in a Memory Clinic

被引：38

作者：

Morinaga, Akiyoshi ^{[1
,2
]}

Ono, Kenjiro ^{[1
]}

Ikeda, Tokuhei ^{[1
]}

Ikeda, Yoshihisa ^{[1
]}

Shima, Keisuke ^{[1
]}

Noguchi-Shinohara, Moeko ^{[1
,3
]}

Samuraki, Miharu ^{[1
,4
]}

Yanase, Daisuke ^{[1
]}

Yoshita, Mitsuhiro ^{[1
]}

Iwasa, Kazuo ^{[1
]}

Mastunari, Ichiro ^{[5
]}

Yamada, Masahito ^{[1
]}

机构：

[1] Kanazawa Univ, Grad Sch Med Sci, Dept Neurol & Neurobiol Aging, Kanazawa, Ishikawa 9208640, Japan

[2] Natl Hosp Org Iou Hosp, Dept Neurol, Kanazawa, Ishikawa, Japan

[3] Ishikawa Prefectural Cent Hosp, Dept Neurol, Kanazawa, Ishikawa, Japan

[4] Keiju Med Ctr, Dept Neurol, Nanao, Japan

[5] Med & Pharmacol Res Ctr Fdn, Hakui, Japan

来源：

DEMENTIA AND GERIATRIC COGNITIVE DISORDERS | 2010年 / 30卷 / 04期

关键词：

Alzheimer's disease; MRI; CBF-SPECT; FDG-PET; CSF biomarkers; Amyloid beta-protein 1-42; Total tau; Phosphorylated tau; MILD COGNITIVE IMPAIRMENT; CSF BIOMARKERS; TAU-PROTEIN; DEMENTIA; ATROPHY; IMAGES; HIPPOCAMPAL; PERFORMANCE; PIB;

D O I：

10.1159/000320265

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

Background/Aim: Magnetic resonance imaging (MRI), cerebral blood flow single photon emission computed tomography (CBF-SPECT), fluorodeoxyglucose-positron emission tomography (FDG-PET) and cerebrospinal fluid (CSF) biomarkers are used for the diagnosis of Alzheimer's disease (AD). We aimed to reveal the relative sensitivity of these tools in a memory clinic setting. Methods: In 207 patients with probable AD in our memory clinic, medial temporal lobe atrophy on MRI, hypoperfusion/hypometabolism of the parietotemporal lobe and posterior cingulate gyrus in ethylcysteinate dimer-CBF-SPECT/FDG-PET, and abnormalities of CSF amyloid beta-protein 1-42, total tau and phosphorylated tau were evaluated as findings characteristic of AD. Results: The AD findings were observed in 77.4% of all AD patients with MRI, 81.6% with CBF-SPECT, 93.1% with FDG-PET and 94.0% with CSF biomarkers. At the stage of Clinical Dementia Rating (CDR) 0.5, CSF biomarkers were the most sensitive (90.0%); at the stage of CDR 1, FDG-PET (96.7%) and CSF biomarkers (95.5%) were highly sensitive. At the stage of CDR 2, all tools showed high positive percentages. Conclusion: The diagnosis of AD was most often supported by CSF biomarkers and FDG-PET at the early stage of dementia (CDR 1) and by CSF biomarkers at the earlier stage (CDR 0.5). Copyright (C) 2010 S. Karger AG, Basel

引用

页码：285 / 292

页数：8